Edition:
United States

Pluristem Therapeutics Inc (PSTI.OQ)

PSTI.OQ on NASDAQ Stock Exchange Capital Market

1.50USD
26 Jul 2016
Change (% chg)

$-0.01 (-0.66%)
Prev Close
$1.51
Open
$1.48
Day's High
$1.50
Day's Low
$1.48
Volume
1,794
Avg. Vol
23,391
52-wk High
$2.44
52-wk Low
$0.74

PSTI.OQ

Chart for PSTI.OQ

About

Pluristem Therapeutics Inc. (Pluristem) is a bio-therapeutics company developing off-the-shelf allogeneic cell therapy products for the treatment of multiple ischemic and inflammatory conditions. The Company focuses on cardiovascular, orthopedic, pulmonary, hematological and women's health diseases. The Company is focused on the... (more)

Overall

Beta: 0.78
Market Cap(Mil.): $121.04
Shares Outstanding(Mil.): 80.16
Dividend: --
Yield (%): --

Financials

  PSTI.OQ Industry Sector
P/E (TTM): -- 41.28 37.71
EPS (TTM): -0.29 -- --
ROI: -47.22 -9.20 14.43
ROE: -50.39 -9.24 15.61

BRIEF-Pluristem advances its U.S. FDA trial in hematologic indication

* Pluristem advances its U.S. FDA trial in hematologic indication

Jul 11 2016

BRIEF-Pluristem completes enrollment of 150 patients in phase II intermittent claudication trial

* Pluristem completes enrollment of 150 patients in phase ii intermittent claudication trial Source text for Eikon: Further company coverage: (Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223 8780)

May 16 2016

BRIEF-RPT-Pluristem granted two cell therapy patents in Japan

* Japan (not 'apan') patent office has granted company two key cell therapy patents

Apr 13 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Reuters Investment Profile
$20.00
Provider : Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.